A first-in-human, phase I clinical trial evaluating Antifibrinolytic activity of BT-114143 various bleeding-related conditions caused by hyperfibrinolysis.

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

A first-in-human, phase I clinical trial evaluating Antifibrinolytic activity of BT-114143 various bleeding-related conditions caused by hyperfibrinolysis.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BT 114143 (Primary)
Indications Haemorrhage
Focus Adverse reactions; First in man
Sponsors ScinnoHub Pharmaceutical

Most Recent Events

02 Feb 2024 thes request sent,drug moa-IV
02 Feb 2024 New trial record
31 Jan 2024 According to ScinnoHub Pharmaceuticals media release , the company is planning to apply for a U.S. Food and Drug Administration (FDA) IND application.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com